INTELLIA THERAPEUTICS INC's ticker is NTLA and the CUSIP is 45826J105. A total of 299 filers reported holding INTELLIA THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 1.39 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $69,311 | -29.4% | 2,192 | -8.9% | 0.04% | -27.6% |
| Q2 2023 | $98,117 | +0.9% | 2,406 | -7.8% | 0.06% | +7.4% |
| Q1 2023 | $97,275 | -22.8% | 2,610 | -27.7% | 0.05% | -18.2% |
| Q4 2022 | $125,953 | -17.1% | 3,610 | +32.7% | 0.07% | +8.2% |
| Q3 2022 | $152,000 | +9.4% | 2,720 | +1.0% | 0.06% | +17.3% |
| Q2 2022 | $139,000 | +41.8% | 2,694 | +99.1% | 0.05% | +18.2% |
| Q1 2022 | $98,000 | -41.7% | 1,353 | -5.1% | 0.04% | -30.2% |
| Q4 2021 | $168,000 | -48.3% | 1,425 | -41.1% | 0.06% | -55.9% |
| Q3 2021 | $325,000 | -21.1% | 2,419 | -4.8% | 0.14% | -15.4% |
| Q2 2021 | $412,000 | -10.8% | 2,542 | -55.9% | 0.17% | -13.3% |
| Q1 2021 | $462,000 | +50.0% | 5,761 | +1.7% | 0.20% | +52.3% |
| Q4 2020 | $308,000 | -2.8% | 5,662 | -64.5% | 0.13% | -22.9% |
| Q3 2020 | $317,000 | -16.6% | 15,927 | -12.0% | 0.17% | -7.8% |
| Q2 2020 | $380,000 | – | 18,100 | – | 0.18% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Discovery Value Fund | 561,561 | $17,756,559 | 9.73% |
| MPM BioImpact LLC | 544,639 | $17,221,485 | 4.60% |
| Casdin Capital, LLC | 1,178,075 | $37,250,732 | 4.12% |
| HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | 1,145,091 | $36,207,777 | 3.72% |
| Atlas Venture Associates IX, LLC | 10,000 | $316,200 | 2.69% |
| Deep Track Capital, LP | 2,000,000 | $63,240,000 | 2.44% |
| ARK Investment Management | 9,948,629 | $314,575,638 | 2.41% |
| Merlin Capital, Inc | 18,526 | $585,792 | 2.19% |
| Orchard Capital Management, LLC | 159,155 | $5,032,481 | 1.86% |
| TANG CAPITAL MANAGEMENT LLC | 397,600 | $12,572,112 | 1.77% |